{"filings":[{"id":670319,"accession_number":"0001110803-26-000124","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2026-05-26T21:28:17+00:00","items":["5.07","9.01"],"status":"ready","headline":"Illumina shareholders elect all nine board nominees; ratify auditor and say-on-pay at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine director nominees elected; Anna Richo received 8.4M against votes (6.5% of votes cast).","Ernst & Young ratified as independent auditor for FY ending Jan 3, 2027 with 133.2M for, 7.8M against.","Advisory approval of named executive officer compensation passed with 121.7M for, 8.5M against.","Quorum of 141.0M votes (92.85% of outstanding shares) present at May 21, 2026 meeting.","Final voting results certified by Inspector of Election on May 22, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91362,"accession_number":"0001110803-26-000087","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Illumina Q1 revenue up 4.8% to $1.09B; non-GAAP EPS $1.15, raises FY2026 guidance; new $1.5B buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.09B (+4.8% YoY); GAAP EPS $0.87, non-GAAP EPS $1.15 vs prior year $0.97.","GAAP operating margin 19.2%, non-GAAP 21.9%; free cash flow $251M vs $208M prior year.","FY2026 guidance raised: revenue $4.52-$4.62B, non-GAAP EPS $5.15-$5.30.","Board authorized new $1.5B share repurchase program; $314M remains from prior $1.5B authorization.","Cash and short-term investments $1.16B; operating cash flow $289M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":1091000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91361,"accession_number":"0001110803-26-000082","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Illumina names David King to board; three directors to retire in May 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Drs. Frances Arnold, Robert Epstein, and Gary Guthart will retire as directors effective May 21, 2026.","Retirements are not due to any dispute with the company or board.","Board nominated David P. King for election at the 2026 annual meeting.","King brings operating, board, and regulatory experience across healthcare and life sciences."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101388,"accession_number":"0001110803-26-000018","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Illumina Q4 revenue $1.16B (+5%), GAAP EPS $2.16; guides FY2026 rev $4.5-$4.6B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.16B in Q4 2025, up 5% YoY; ex-China revenue up 8%.","GAAP diluted EPS $2.16; non-GAAP diluted EPS $1.35.","FY2025 revenue $4.34B flat YoY; GAAP EPS $5.45, non-GAAP EPS $4.84.","FY2026 guidance: revenue $4.5-$4.6B (4-6% growth); non-GAAP EPS $5.05-$5.20.","Completed SomaLogic acquisition; China MOFCOM export ban lifted; launched Billion Cell Atlas with partners."],"consensus_eps_estimate":null,"consensus_eps_actual":5.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":4343000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101387,"accession_number":"0001110803-26-000014","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["2.01","8.01","9.01"],"status":"ready","headline":"Illumina completes $350M acquisition of SomaLogic from Standard BioTools","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price $350M in cash plus up to $75M in performance milestones and royalties.","SomaLogic's proteomics tech (SomaScan, SomaSignal) expands Illumina's multiomics portfolio.","Acquisition funded with cash on hand; financial impact discussed on Feb 5, 2026 earnings call.","Builds on co-development partnership established in 2021 for NGS-based proteomics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101386,"accession_number":"0001110803-26-000009","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Illumina prelim Q4 rev $1.155B (+5% YoY); FY rev flat at $4.34B; EPS ranges given","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue ~$1.155B, up 5% YoY (4% constant currency); ex-China rev ~$1.1B up 7%.","FY2025 revenue ~$4.34B flat YoY; ex-China rev ~$4.1B up 2%.","Q4 GAAP diluted EPS $2.14-$2.17; non-GAAP diluted EPS $1.27-$1.30.","FY2025 GAAP diluted EPS $5.42-$5.45; non-GAAP $4.76-$4.79.","Full Q4/FY results expected after market close on Feb 5, 2026; preliminary numbers subject to audit."],"consensus_eps_estimate":null,"consensus_eps_actual":5.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":4343000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101385,"accession_number":"0001110803-26-000006","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Illumina appoints Dr. Eric Green as CMO; CCO Everett Cunningham resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Eric Green (former NHGRI director) named Chief Medical Officer, effective Feb 2, 2026.","Everett Cunningham resigns as Chief Commercial Officer effective Jan 16, 2026 to become CEO of a life science tools company.","CEO Jacob Thaysen will serve as interim CCO until a permanent successor is named.","Illumina to present at J.P. Morgan Healthcare Conference on Jan 13, 2026 at 7:30 AM PT."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117750,"accession_number":"0001193125-25-297576","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Illumina closes $500M 4.750% notes due 2030; proceeds for refinancing and SomaLogic acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Closed $500M public offering of 4.750% notes due December 12, 2030, issued under existing indenture.","Net proceeds earmarked to refinance $500M of 5.800% notes maturing Dec 2025 and fund SomaLogic acquisition.","Interest payable semi-annually at 4.750%; notes unsecured and may be redeemed at company's option.","Offering registered on Form S-3; trustee is U.S. Bank Trust Company, National Association."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117749,"accession_number":"0001193125-25-277870","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Illumina issues $500M of 4.750% notes due 2030, proceeds to repay existing debt and fund SomaLogic acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $500M aggregate principal of 4.750% notes due 2030 via underwriters Goldman Sachs & Co. LLC and BofA Securities.","Offering expected to close on November 25, 2025, subject to customary conditions.","Proceeds may be used to repay its 5.800% notes due December 12, 2025 and to fund the proposed SomaLogic acquisition and related fees.","Notes issued under existing shelf registration statement on Form S-3 (File No. 333-281921)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117748,"accession_number":"0001110803-25-000071","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Illumina Q3 revenue $1.08B flat YoY, non-GAAP EPS $1.34 beats; raises FY EPS guidance to $4.65-$4.75","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 GAAP diluted EPS $0.98, non-GAAP diluted EPS $1.34; non-GAAP operating margin 24.5%.","Revenue $1.08B flat YoY on reported and constant currency; returned to growth ex-China.","FY2025 guidance raised: revenue decline narrowed to (1.5%)-(0.5%), non-GAAP EPS to $4.65-$4.75 from $4.45-$4.55.","Repurchased 1.2M shares for $120M at avg $97.10; cash flow from ops $284M, free cash flow $253M.","Launched new products: 5-base solution, Constellation mapped read tech, BioInsight, and Illumina Protein Prep."],"consensus_eps_estimate":null,"consensus_eps_actual":3.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":3184000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134191,"accession_number":"0001110803-25-000057","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Illumina Q2 EPS $1.19 non-GAAP, revenue $1.06B; raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.059B down 3% YoY; GAAP EPS $1.49, non-GAAP EPS $1.19 vs. $1.09 prior year.","FY2025 guidance raised: revenue decline (2.5%)-(0.5%), non-GAAP op margin 22%-22.5%, EPS $4.45-$4.55.","Repurchased 4.5M shares for $380M at avg $84.66; ~$800M remaining authorization.","Signed definitive agreement to acquire SomaLogic from Standard BioTools; close expected H1 2026.","Q2 free cash flow $204M; cash and short-term investments $1.16B."],"consensus_eps_estimate":null,"consensus_eps_actual":2.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":2100000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150968,"accession_number":"0001193125-25-144290","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Illumina to acquire SomaLogic for $350M cash plus up to $75M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Illumina will acquire SomaLogic's aptamer-based proteomics business from Standard BioTools for $350M cash at closing, plus up to $75M in milestones and royalties.","Transaction includes SomaLogic's SomaScan assay, CLIA/CAP lab in Boulder, CO, and ~250 employees; builds on co-development since 2021.","Illumina expects the business to become profitable on a non-GAAP basis in 2027, with operating margins in line with Illumina by 2028.","Closing expected in first half of 2026, subject to HSR and other customary conditions; termination fee of $14.5M under certain circumstances.","Illumina Protein Prep (SomaScan on NGS) already has ~40 early-access customers, full availability in Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150967,"accession_number":"0001110803-25-000051","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Illumina stockholders approve amended equity plan adding ~6.3M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved the Second Amended and Restated 2015 Stock and Incentive Plan, adding up to 6.3M new shares plus carryover from prior plan.","All 11 director nominees elected; Ernst & Young LLP ratified as independent auditor for FY2025.","Advisory say-on-pay passed with ~89% of votes cast (excluding broker non-votes).","Plan covers incentive stock options, nonstatutory options, stock grants, units, SARs, and cash awards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150966,"accession_number":"0001110803-25-000044","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Illumina Q1 core rev $1.04B (-1% YoY) but cuts FY2025 guidance on tariffs & China","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.82; non-GAAP $0.97; GAAP op margin 15.8%, non-GAAP 20.4%.","FY2025 core revenue now seen declining 1-3% constant currency (prior low single-digit growth).","Non-GAAP EPS guidance cut to $4.20-$4.30 from ~$4.50; tariff costs estimated at $85M (125bps, $0.25 EPS).","Greater China 2025 revenue expected $165-$185M (Q1 recognition $72M); $100M cost reduction program initiated.","Q1 free cash flow $208M; $200M in share repurchases during quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":1041000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169874,"accession_number":"0001110803-25-000032","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Illumina elects Dr. Scott Gottlieb as Chair, appoints Keith Meister to board; Stephen MacMillan retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Scott Gottlieb elected non-executive Chair of Illumina's Board, effective March 28, 2025.","Keith Meister (Corvex Management founder) joins Board on March 28, 2025.","Stephen MacMillan resigns from Board effective March 28, 2025; no dispute with company.","Meister will stand for election at 2025 annual meeting; Gottlieb has served since 2020."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169873,"accession_number":"0001110803-25-000029","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Illumina CIO Carissa Rollins to retire effective April 11, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CIO Carissa Rollins notified Illumina on March 18, 2025 of her retirement.","Retirement effective as of April 11, 2025.","No replacement or interim CIO named in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169872,"accession_number":"0001110803-25-000025","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Illumina responds to China export ban, cuts FY2025 EPS guidance to ~$4.50","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["China MOFCOM prohibited Illumina from exporting sequencing instruments into China effective March 4, 2025.","FY2025 Core Illumina non-GAAP diluted EPS expected to be approximately $4.50.","Implementing incremental ~$100 million cost reduction program for FY2025 to offset China revenue impact.","CEO Jacob Thaysen reaffirms target of high-single-digit revenue growth by 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169871,"accession_number":"0001110803-25-000014","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Illumina Q4 core revenue up 1% to $1.1B; FY2025 guided to low single-digit growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Core Illumina Q4 revenue $1.104B (+1% YoY); GAAP EPS $0.73, non-GAAP EPS $0.95.","Full year core revenue $4.332B (-2% YoY); free cash flow $1.07B.","FY2025 guidance: core revenue $4.28B-$4.4B; non-GAAP Op margin ~23%; non-GAAP EPS $4.50-$4.65.","China Ministry of Commerce impact excluded from guidance; company notes current macro/political environment.","Key partnerships announced: NVIDIA, UK Biobank proteomics, Regeneron/Truveta Genome Project."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":4372000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169870,"accession_number":"0001110803-25-000009","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Illumina reports Q4 core revenue $1.10B (+1% YoY); FY2025 outlook low-single-digit growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 core revenue $4.33B (-2% YoY constant currency); Q4 revenue $1.10B (+1% YoY).","GAAP diluted EPS: Q4 ~$0.77-$0.79, FY ~$5.65-$5.67; Non-GAAP Q4 ~$0.91-$0.93, FY ~$4.12-$4.14.","FY2025 guidance: reported revenue $4.28B-$4.4B, non-GAAP operating margin ~23%, non-GAAP EPS growth ~10%.","FY2024 free cash flow $1.07B (operating cash flow $1.21B less capex).","Preliminary results subject to completion of audit; final results expected Feb 6, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":4372000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169869,"accession_number":"0001110803-25-000011","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K/A","filed_at":"2025-01-14T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Illumina records $14M additional impairment on San Diego property in Q4 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total $32M impairment in Q1 2024 from exiting Foster City campus and another San Diego property.","Additional $14M right-of-use asset impairment in Q4 2024 for the San Diego property; no remaining assets there.","Company continues to evaluate options for remaining Foster City campus.","All real estate exit charges will be excluded from non-GAAP financial metrics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186927,"accession_number":"0001110803-24-000049","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Illumina Q3 Core revenue $1.08B (-2% YoY); raises FY24 non-GAAP EPS guide to $4.05-$4.15","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Core Illumina revenue $1.08B, down 2% YoY; GAAP diluted EPS $4.03, non-GAAP $1.14.","Lowered FY2024 Core revenue guidance to ~3% decline; Q4 revenue expected ~$1.07B.","Raised FY2024 non-GAAP operating margin guidance to 21%-21.5% and non-GAAP diluted EPS to $4.05-$4.15.","Free cash flow $284M in Q3, up from $94M YoY; cash & short-term investments $939M.","Introduced MiSeq i100 Series, FDA approval for TSO Comprehensive, GRAIL spin-off completed June 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-8.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":3268000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186926,"accession_number":"0000950157-24-001364","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2024-10-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Illumina General Counsel Charles Dadswell to exit; Scott Davies named interim GC","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dadswell steps down as General Counsel and Secretary effective Oct 3, 2024; serves as advisor to CEO/Board through Mar 31, 2025.","Scott Davies, VP Legal – Chief Corporate Counsel, appointed Interim General Counsel and Secretary.","Dadswell eligible for $600K cash lump-sum payment plus regular compensation during advisory period upon satisfactory service.","Separation Agreement provides $620K severance (52 weeks salary), COBRA for 12 months, outplacement, and 2024 bonus if unpaid."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203468,"accession_number":"0001193125-24-215883","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["1.02","8.01","9.01"],"status":"ready","headline":"Illumina repays $761M credit facility, issues $500M 4.650% notes due 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repaid all $761M outstanding under 364-day delayed draw credit agreement on Sept 9, 2024.","Issued $500M aggregate principal of 4.650% notes maturing Sept 9, 2026.","Net proceeds from notes plus cash on hand used to repay the credit facility.","Notes are unsecured, interest payable semi-annually; redeemable at Illumina's option.","Underwriters included J.P. Morgan Securities and Goldman Sachs & Co. LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203467,"accession_number":"0001193125-24-214335","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Illumina prices $500M of 4.650% notes due 2026; proceeds to repay GRAIL spin-off debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$500M aggregate principal of 4.650% notes maturing 2026 in an underwritten public offering.","Offering expected to close Sept 9, 2024, subject to customary closing conditions.","Net proceeds to repay part of $750M 364-day delayed draw credit agreement used for GRAIL spin-off.","Offering conducted under effective shelf registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203466,"accession_number":"0001110803-24-000042","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Illumina Q2 core revenue $1.09B (-6% YoY); lowers FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Core Illumina Q2 revenue $1.09B, down 6% YoY and 6% constant currency; up 3% from Q1.","Core Illumina GAAP EPS $0.41; non-GAAP EPS $1.09; non-GAAP operating margin 22.2%.","Lowered FY2024 core revenue guidance to decline 2-3% (constant currency down 1.5-2.5%).","Raised FY2024 non-GAAP operating margin guidance to 20.5-21%; non-GAAP EPS guidance $3.80-$3.95.","Consolidated GAAP net loss $1.988B includes $1.886B goodwill impairment on GRAIL; GRAIL spin-off completed June 24."],"consensus_eps_estimate":null,"consensus_eps_actual":-13.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":2188000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219887,"accession_number":"0001110803-24-000038","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K/A","filed_at":"2024-06-27T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Illumina estimates $1.466B goodwill and $420M IPR&D impairment charges for GRAIL in Q2 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Goodwill impairment charge of $1,466M related to GRAIL, representing full remaining carrying value as of March 31, 2024.","IPR&D intangible asset impairment charge of $420M for GRAIL in Q2 2024.","No material future cash expenditures expected from these impairment charges.","Charges will be excluded from non-GAAP financial metrics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219886,"accession_number":"0001110803-24-000037","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K/A","filed_at":"2024-06-27T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Illumina completes GRAIL spin-off; expects $1.9B in Q2 impairment charges","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Spin-off closed June 24, 2024; Illumina distributed 85.5% of GRAIL shares (1-for-6 ratio) and retained 14.5% stake.","Illumina contributed $974M cash to GRAIL (funded by a $750M 364-day term loan at ~6.69%, maturing June 2025).","Pro forma financials reflect expected Q2 2024 goodwill impairment of $1,466M and IPR&D impairment of $420M.","Pro forma for spin-off, 2023 net income would have been $219M vs. historical loss of $1,161M; Q1 2024 pro forma net income $56M vs. historical loss $126M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219894,"accession_number":"0001193125-24-167025","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["1.01","2.01","8.01","9.01"],"status":"ready","headline":"Illumina completes spin-off of GRAIL, retains 14.5% stake; GRAIL to trade as GRAL","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Spin-off effective June 24, 2024: Illumina distributed 85.5% of GRAIL shares (1 share GRAIL per 6 shares ILMN), retains 14.5%.","GRAIL begins regular-way trading on Nasdaq as 'GRAL' on June 25, 2024.","Illumina drew $750M term loan at ~6.70% on June 20 to fund GRAIL's cash balance in connection with divestment.","Illumina to report Q2 2024 earnings on August 6 and host Strategy Update on August 13.","No gain/loss recognized for U.S. shareholders on distribution except for cash in lieu of fractional shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219893,"accession_number":"0001193125-24-162068","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Illumina enters $750M 364-day delayed draw credit facility for GRAIL divestiture funding","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Credit facility of $750 million entered June 17, 2024, with JPMorgan as administrative agent.","Proceeds to fund GRAIL's balance sheet in connection with planned GRAIL divestiture.","Facility expected to be drawn in full on June 20, 2024, maturing June 19, 2025.","Interest rate variable: currently approx 6.70%; based on SOFR or base rate plus spread.","No borrowings outstanding as of filing; covenant includes max total leverage ratio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219885,"accession_number":"0001193125-24-155272","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K/A","filed_at":"2024-06-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Illumina clarifies GRAIL spin-off dates: distribution effective June 24, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Distribution effective 12:01 A.M. NYC time on June 24; GRAIL begins regular-way trading June 25 under ticker GRAL.","GRAIL stock trades when-issued on Nasdaq as GRALV from June 12 through June 24.","Illumina common has two markets June 12–24: ILMN (with GRAIL entitlement) and ILMNV (ex-distribution). After June 25, only ILMN trades.","Spin-off is a pro rata dividend of at least 85.5% of GRAIL shares to Illumina stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219892,"accession_number":"0001193125-24-153239","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["2.05","8.01"],"status":"ready","headline":"Illumina board approves GRAIL spin-off; distribution set for June 24, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders receive 1 GRAIL share per 6 Illumina shares held at close on June 13, 2024 (record date).","Distribution effective 12:01 AM NYC time on June 24, 2024; GRAIL expected to trade 'regular way' on Nasdaq on June 25 under ticker 'GRAL'.","Illumina estimates $35-$50M incremental costs for spin-off, mainly legal and advisory fees, substantially incurred by Q3 2024.","Spin-off approval triggers potential goodwill impairment test; carrying value includes $1.466B goodwill and $561M IPR&D related to GRAIL.","Conditions include satisfaction or waiver of conditions in GRAIL's Form 10; no stockholder vote or action required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219891,"accession_number":"0001110803-24-000030","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Illumina shareholders elect all 11 director nominees, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 11 director nominees elected; Jacob Thaysen received highest support with 130.2M votes for.","Ernst & Young ratified as independent auditor for FY2024: 133.8M for, 6.8M against.","Advisory say-on-pay approved: 113.5M for, 16.7M against, 1.1M abstain.","Annual meeting held May 16, 2024; 141.8M shares represented in person or proxy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219884,"accession_number":"0001110803-24-000025","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K/A","filed_at":"2024-05-03T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Illumina records $75M in impairments on Foster City, San Diego campus exits; $142M assets at risk","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Recorded $43M right-of-use asset and leasehold improvement impairment in Q4 2023 for Foster City campus exit.","Additional $18M right-of-use asset impairment in Q1 2024 for Foster City and San Diego properties.","Recorded $14M leasehold improvement impairment in Q1 2024 related to Foster City campus.","Remaining assets on Foster City and San Diego properties total ~$142M as of March 31, 2024.","Company may incur further charges but cannot estimate timing or amount; charges excluded from non-GAAP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219890,"accession_number":"0001110803-24-000019","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Illumina Q1 2024: Core rev -2% to $1.06B; GAAP loss $0.79; GRAIL divestiture on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Core Illumina revenue $1.06B, down 2% YoY; GAAP operating margin 11.0%, non-GAAP 20.6%.","GAAP diluted loss per share ($0.79) vs. $0.02 EPS in Q1 2023; non-GAAP EPS $0.09 vs. $0.08.","FY2024 guidance reaffirmed: core revenue approximately flat YoY; non-GAAP operating margin ~20%.","GRAIL divestiture: received European Commission approval; target to finalize terms by end of Q2 2024.","In capital markets divestiture scenario, Illumina to provide GRAIL with ~$1B funding."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":1076000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}